Skip to main content
Clinical Trials/NCT03612804
NCT03612804
Completed
Not Applicable

Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment

VA Office of Research and Development3 sites in 1 country944 target enrollmentMay 10, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Smoking Reduction
Sponsor
VA Office of Research and Development
Enrollment
944
Locations
3
Primary Endpoint
Self-reported Smoking Abstinence
Status
Completed
Last Updated
last year

Overview

Brief Summary

This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.

Detailed Description

This trial is a pragmatic randomized trial targeting the care of current smokers who are participating in lung cancer screening at two VA sites. Primary care providers at these sites will be randomized, and half will be offered tools to help integrate proactive smoking cessation support into the lung cancer screening process. Key proactive elements include proactive telephone outreach to all current smokers by a VA Quitline counselor that follows mailed results letters, and providing providers guidance in offering proactive cessation medication support as part of the lung cancer screening process.

Registry
clinicaltrials.gov
Start Date
May 10, 2019
End Date
February 9, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Providers who schedule patients for a lung cancer screening at either of the two VA sites.
  • Patients who participate in lung cancer screening and are current smokers at the time of scheduling their screening exam.

Exclusion Criteria

  • Providers who currently systematically prescribe cessation support medication to all current smokers will be excluded.
  • Patients with urgent findings requiring biopsy/immediate attention on the screening CT will be excluded.
  • Patients with a prior diagnosis of lung cancer or who are receiving active therapy for any cancer, except skin cancer, will be excluded.
  • Patients previously diagnosed with cognitive impairment, dementia, or severe behavioral disorders, or have an indication in chart review of difficulty communicating or participating in telephone counseling sessions will be excluded.

Outcomes

Primary Outcomes

Self-reported Smoking Abstinence

Time Frame: 12 months after lung cancer screening visit

The primary outcome measure is self-reported abstinence from smoking 12 months after lung cancer screening, using information obtained from study surveys and electronic medical records. This measure only applies to patient enrollees.

Secondary Outcomes

  • Cost of Smoking Cessation Care(Time period from lung cancer screening through 12 months after lung cancer screening)
  • Patients' Experience With Telephone Counseling(3 months after lung cancer screening visit)
  • Patients' Motivational Assessment(12 months after lung cancer screening visit)
  • Patients' Perception of Susceptibility to Harm(3 months after lung cancer screening visit)
  • Patients' Self-efficacy Assessment(12 months after lung cancer screening visit)

Study Sites (3)

Loading locations...

Similar Trials